Android app Apple app link

Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential

By Yahoo! Finance   |   1 month ago
Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is a top biotech stock with a Buy rating and $20 price target from Guggenheim. Their focus on selective estrogen receptor degrader breast cancer drugs, particularly palazestrant, shows promise in a $10 billion market.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.